Annual Total Long Term Liabilities
$4.24 M
-$191.00 K-4.31%
March 31, 2024
Summary
- As of February 8, 2025, VTGN annual total long term liabilities is $4.24 million, with the most recent change of -$191.00 thousand (-4.31%) on March 31, 2024.
- During the last 3 years, VTGN annual total long term liabilities has fallen by -$7.87 million (-64.97%).
- VTGN annual total long term liabilities is now -64.97% below its all-time high of $12.11 million, reached on March 31, 2021.
Performance
VTGN Long Term Liabilities Chart
Add series to chart(max: 6)
company, ETF, index, featured screener or watchlist
Highlights
High & Low
Earnings dates
Quarterly Long Term Liabilities
$2.00 M
-$510.00 K-20.33%
September 30, 2024
Summary
- As of February 8, 2025, VTGN quarterly total long term liabilities is $2.00 million, with the most recent change of -$510.00 thousand (-20.33%) on September 30, 2024.
- Over the past year, VTGN quarterly long term liabilities has stayed the same.
- VTGN quarterly long term liabilities is now -84.32% below its all-time high of $12.75 million, reached on September 30, 2020.
Performance
VTGN Quarterly Long Term Liabilities Chart
Add series to chart(max: 6)
company, ETF, index, featured screener or watchlist
Highlights
High & Low
Earnings dates
Long Term Liabilities Formula
Long-Term Liabilities = Long-Term Debt + Deferred Tax Liabilities + Pension Liabilities + Other Long-Term Liabilities
VTGN Long Term Liabilities Trends
| PeriodPeriod | AnnualAnnual | QuarterlyQuarterly |
|---|---|---|
| 1 y1 year | -4.3% | 0.0% |
| 3 y3 years | -65.0% | 0.0% |
| 5 y5 years | +2.6% | 0.0% |
VTGN Long Term Liabilities Highs & Lows
| PeriodPeriod | Annual vs highAnnual vs high | Annual vs lowAnnual vs low | Quarter. vs highQuarter. vs high | Quarter. vs lowQuarter. vs low | |
|---|---|---|---|---|---|
| 3 y | 3-year | -65.0% | +1.9% | -60.4% | at low |
| 5 y | 5-year | -65.0% | +2.6% | -84.3% | at low |
| alltime | all time | -65.0% | -100.0% | -84.3% | -100.0% |
VistaGen Therapeutics Long Term Liabilities History
| Date | Annual | Quarterly |
|---|---|---|
| Sep 2024 | - | $2.00 M(-20.3%) |
| Jun 2024 | - | $2.51 M(-40.9%) |
| Mar 2024 | $4.24 M(-4.3%) | $4.24 M(+17.3%) |
| Dec 2023 | - | $3.62 M(-0.6%) |
| Sep 2023 | - | $3.64 M(-11.9%) |
| Jun 2023 | - | $4.13 M(-6.8%) |
| Mar 2023 | $4.43 M(+6.5%) | $4.43 M(-6.6%) |
| Dec 2022 | - | $4.75 M(-6.0%) |
| Sep 2022 | - | $5.05 M(+34.8%) |
| Jun 2022 | - | $3.75 M(-10.0%) |
| Mar 2022 | $4.16 M(-65.6%) | $4.16 M(+0.6%) |
| Dec 2021 | - | $4.14 M(-65.3%) |
| Sep 2021 | - | $11.93 M(-0.8%) |
| Jun 2021 | - | $12.02 M(-0.7%) |
| Mar 2021 | $12.11 M(+38.8%) | $12.11 M(-2.9%) |
| Dec 2020 | - | $12.48 M(-2.1%) |
| Sep 2020 | - | $12.75 M(+40.0%) |
| Jun 2020 | - | $9.11 M(+4.3%) |
| Mar 2020 | $8.73 M(+111.1%) | $8.73 M(+2.8%) |
| Dec 2019 | - | $8.49 M(+2.9%) |
| Sep 2019 | - | $8.25 M(+2.9%) |
| Jun 2019 | - | $8.01 M(+93.8%) |
| Mar 2019 | $4.14 M(+42.4%) | $4.14 M(+7.1%) |
| Dec 2018 | - | $3.86 M(+7.6%) |
| Sep 2018 | - | $3.59 M(+13.6%) |
| Jun 2018 | - | $3.16 M(+8.9%) |
| Mar 2018 | $2.90 M(+67.9%) | $2.90 M(+9.4%) |
| Dec 2017 | - | $2.65 M(+10.3%) |
| Sep 2017 | - | $2.40 M(+17.9%) |
| Jun 2017 | - | $2.04 M(+17.9%) |
| Mar 2017 | $1.73 M | $1.73 M(+22.2%) |
| Dec 2016 | - | $1.42 M(+24.2%) |
| Date | Annual | Quarterly |
|---|---|---|
| Sep 2016 | - | $1.14 M(+14.6%) |
| Jun 2016 | - | $993.60 K(-54.3%) |
| Mar 2016 | $2.17 M(-36.6%) | $2.17 M(+44.0%) |
| Dec 2015 | - | $1.51 M(+66.1%) |
| Sep 2015 | - | $908.70 K(-31.7%) |
| Jun 2015 | - | $1.33 M(-61.1%) |
| Mar 2015 | $3.42 M(-56.4%) | $3.42 M(-53.0%) |
| Dec 2014 | - | $7.28 M(-33.0%) |
| Sep 2014 | - | $10.86 M(+9.1%) |
| Jun 2014 | - | $9.96 M(+26.7%) |
| Mar 2014 | $7.86 M(-28.7%) | $7.86 M(-5.2%) |
| Dec 2013 | - | $8.29 M(-16.4%) |
| Sep 2013 | - | $9.91 M(+4.9%) |
| Jun 2013 | - | $9.45 M(-14.3%) |
| Mar 2013 | $11.02 M(+284.8%) | $11.02 M(+33.3%) |
| Dec 2012 | - | $8.27 M(+110.1%) |
| Sep 2012 | - | $3.94 M(+54.8%) |
| Jun 2012 | - | $2.54 M(-11.2%) |
| Mar 2012 | $2.86 M(>+9900.0%) | $2.86 M(-2.7%) |
| Dec 2011 | - | $2.94 M(-4.0%) |
| Sep 2011 | - | $3.07 M(-4.4%) |
| Jun 2011 | - | $3.21 M(>+9900.0%) |
| Mar 2011 | - | $0.00(0.0%) |
| Dec 2010 | $0.00(0.0%) | $0.00(0.0%) |
| Sep 2010 | - | $0.00(0.0%) |
| Jun 2010 | - | $0.00(0.0%) |
| Mar 2010 | - | $0.00(0.0%) |
| Dec 2009 | $0.00(0.0%) | $0.00(0.0%) |
| Sep 2009 | - | $0.00(0.0%) |
| Jun 2009 | - | $0.00(0.0%) |
| Dec 2008 | $0.00 | $0.00(0.0%) |
| Jun 2008 | - | $0.00(0.0%) |
| Mar 2008 | - | $0.00 |
FAQ
- What is VistaGen Therapeutics annual total long term liabilities?
- What is the all time high annual total long term liabilities for VistaGen Therapeutics?
- What is VistaGen Therapeutics annual total long term liabilities year-on-year change?
- What is VistaGen Therapeutics quarterly total long term liabilities?
- What is the all time high quarterly long term liabilities for VistaGen Therapeutics?
- What is VistaGen Therapeutics quarterly long term liabilities year-on-year change?
What is VistaGen Therapeutics annual total long term liabilities?
The current annual total long term liabilities of VTGN is $4.24 M
What is the all time high annual total long term liabilities for VistaGen Therapeutics?
VistaGen Therapeutics all-time high annual total long term liabilities is $12.11 M
What is VistaGen Therapeutics annual total long term liabilities year-on-year change?
Over the past year, VTGN annual total long term liabilities has changed by -$191.00 K (-4.31%)
What is VistaGen Therapeutics quarterly total long term liabilities?
The current quarterly long term liabilities of VTGN is $2.00 M
What is the all time high quarterly long term liabilities for VistaGen Therapeutics?
VistaGen Therapeutics all-time high quarterly total long term liabilities is $12.75 M
What is VistaGen Therapeutics quarterly long term liabilities year-on-year change?
Over the past year, VTGN quarterly total long term liabilities has changed by $0.00 (0.00%)